Patient characteristics | GAVE (n=216) n (%) or median (IQR 25th-75th) | No GAVE (n=1823) n (%) or median (IQR 25th-75th) | p-value |
---|---|---|---|
Demographics | |||
Age at SSc disease onset*, years | 49.51 (40.04-58.21) | 46.70 (35.97-56.70) | 0.051 |
Female | 188 (87.0%) | 1553 (85.5%) | 0.535 |
Caucasian ethnicity | 183 (91.5%) | 1522 (90.9%) | 0.768 |
Diffuse disease subtype | 72 (35.3%) | 401 (24.1%) | 0.001 |
Follow-up, years | 4.27 (1.72-8.39) | 3.39 (1.00-7.25) | 0.003 |
Autoantibodies** | |||
ANA positive | 204 (98.6%) | 1615 (94.9%) | 0.019 |
ANA Pattern | |||
Centromere | 99 (49.3%) | 833 (52.4%) | 0.397 |
Speckled | 79 (39.7%) | 461 (29.3%) | 0.003 |
Nucleolar | 47 (23.5%) | 387 (24.6%) | 0.725 |
Homogenous | 19 (9.6%) | 346 (22.2%) | <0.001 |
ENA subtype positivity | |||
Anti-Scl70 | 8 (4.0%) | 264 (16.1%) | <0.001 |
Scl/PM | 0 (0.0%) | 33 (2.0%) | 0.042 |
U1RNP | 7 (3.5%) | 121 (7.4%) | 0.041 |
RNA Polymerase III positive | 46 (24.9%) | 129 (8.3%) | <0.001 |
Anaemia | 79 (38.0%) | 258 (15.2%) | <0.001 |
Drop in Hb of >10g/l between visits | 91 (53.8%) | 561 (44.3%) | 0.019 |
Clinical manifestations** | |||
Digital ulcers | 117 (54.2%) | 736 (41.0%) | <0.001 |
Digital pitting | 142 (67.0%) | 1013 (58.0%) | 0.012 |
Digital amputation | 41 (19.1%) | 221 (12.4%) | 0.006 |
Telangiectasia | 198 (93.0%) | 1486 (85.1%) | 0.002 |
Calcinosis | 105 (48.8%) | 649 (37.6%) | <0.001 |
GORD | 216 (100.0%) | 1659 (92.4%) | <0.001 |
GIT dysmotility | |||
Oesphageal | 107 (49.5%) | 706 (38.7%) | 0.002 |
Bowel | 83 (38.4%) | 427 (23.4%) | <0.001 |
SSc Renal Crisis | 18 (8.3%) | 56 (3.1%) | <0.001 |
ILD | 53 (58.2%) | 477 (64.8%) | 0.218 |
PAH# | 24 (11.1%) | 171 (9.4%) | 0.413 |
Co-morbidities | |||
Smoking history (current or ever) | 121 (56.8%) | 885 (49.9%) | 0.056 |
Ischemic heart disease | 38 (17.8%) | 175 (10.0%) | 0.001 |
Peripheral vascular disease | 18 (11.3%) | 82 (6.9%) | 0.044 |
Concurrent cancer diagnosis | 57 (26.4%) | 378 (20.7%) | 0.055 |
Hospitalisations*** | 130 (63.4%) | 899 (51.6%) | 0.001 |
Medication | |||
Protein Pump Inhibitor | 207 (95.8%) | 1423 (78.1%) | <0.001 |
Histamine 2 receptor antagonist | 73 (33.8%) | 376 (20.6%) | <0.001 |
Anticoagulant medication | 15 (6.9%) | 80 (4.4%) | 0.092 |
Antiplatelet agent | 69 (31.9%) | 534 (29.3%) | 0.419 |
Cyclophosphamide | 20 (9.3%) | 150 (8.2%) | 0.604 |
HRQoL## | |||
Physical component score (PCS) | 53.07 (42.41-58.55) | 53.56 (44.49-58.70) | 0.731 |
Mental component score (MCS) | 39.73 (29.58-49.19) | 43.56 (33.48-52.49) | 0.002 |